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Objective: To compare the treatment outcomes of intensity-modulated radiotherapy with simultaneous integrated
boost (IMRT-SIB) alone to concurrent chemoradiotherapy (CCRT) for locoregionally advanced nasopharyngeal
carcinoma (NPC).
Methods: From November 2001 to December 2009, 333 patients with pathologically diagnosed, locoregionally
advanced NPC were treated by IMRT-SIB with or without weekly cisplatin concurrent chemotherapy at our institute.
Among them, 62 patients received neo- or adjuvant chemotherapy or molecular target drugs were excluded from this
analysis. There were 129 patients received IMRT-SIB alone, and 142 patients received IMRT-SIB with weekly cisplatin
30 mg/m2 for 7 weeks. The radiotherapy protocol was identical for each group.
Results: There were no significant differences in survival between CCRT and IMRT-SIB group in terms of gender, T/N
classifications and concurrent chemoradiotherapy. The 5-year local control (LC), overall survival (OS), disease-free survival
(DFS) and distant metastasis-free survival (DMFS) for the entire group were 87.0%, 79.4%, 69.7 and 83.3%, respectively.
The LC, OS, DFS and DMFS for CCRT and IMRT-SIB alone groups were 80.6% vs. 90.8% (P = 0.10), 71.7% vs. 83.2%
(P = 0.201), 63.9% vs. 74.6% (P = 0.07), and 79.6% vs. 86.0% (P = 0.27), respectively.
Conclusion: Compared to CCRT, IMRT-SIB alone had demonstrated similar disease LC, OS, DFS and DMFS in
locoregionally advanced NPC. Careful radiation target volume design and simultaneous integrated boost may
play a role that overrides the benefit from concurrent chemotherapy. Further investigation with randomized study is
necessary to determine whether IMRT-SIB alone can achieve similar outcomes of concurrent chemoradiotherapy.
Keywords: Locally advanced, Nasopharyngeal carcinoma, Concurrent chemoradiotherapy, Intensity-modulated
radiotherapy with simultaneous integrated boostIntroduction
Majority patients with nasopharyngeal carcinomas (NPC)
present with locoregionally advanced stages at diagnosis,
the treatment modality with concurrent chemoradiother-
apy has demonstrated superior to radiotherapy (RT) alone
in terms of disease locoregional control and survivals,
cisplatin based chemoradiotherapy has improved 5-year
overall survival from 50% to 75% [1-6]. In the past
15-years, IMRT technique has widely utilized in the* Correspondence: li_gao2008@outlook.com
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NPC due to anatomic complexity and benefits in ac-
curately encompassing tumor targets and reducing
organ at risk’s (OAR) toxicities. Two-dimensional (2D) or
3-dimensional techniques (3D) has been used in the previ-
ous published NPC studies, it is unknown whether IMRT
alone with accurate tumor delineations and the technique
of IMRT-SIB could achieve similar outcomes of disease
loco-regional control. The theory supporting this hypoth-
esis is the majority of NPC in Asia are poor or undifferen-
tiated histology, and NPC is a type of sensitive tumor
to RT or CCRT, comparing 2D conventional RT, sophisti-
cated IMRT-SIB provides the advantage of adequate targethis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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oma target volume, and limit toxicity to adjacent critical
structures [7,8]. Several studies have shown that compared
to 2D technique, IMRT improved NPC disease local con-
trols and reduced radiation associated toxicities [9-11]. It
is reasonable to postulate that the local control improve-
ment of nasopharyngeal carcinoma treated by IMRT-SIB
will be translated into overall survival benefit. To investi-
gate whether IMRT-SIB alone can achieve outcomes that
are as effective as the published data on locoregional con-
trol and survival in NPC patients, we conducted a retro-
spective cohort study for patients with locoregionally
advanced NPC that were all treated with IMRT-SIB tech-
nique alone or concurrent with weekly cisplatin. The re-
sults may provide some clinical evidences that IMRT-SIB
may be applied for selected locoregionally advanced NPC.
Methods
Patient’s inclusion criteria
From November 2001 through December 2009, totally
416 pathologically proven nasopharyngeal carcinoma pa-
tients were treated with IMRT-SIB technique in our hos-
pital. There were 333 patients in stage III, IVA/B when
reevaluated according to the 6th UICC staging system,
sixty-two patients were excluded from this study for re-
ceiving induction and/or adjuvant chemotherapy (n = 20),
or epidermal growth factor receptor inhibitors (n = 42).
There were 197 males and 74 females; the median age
was 47 (range, 12-81). Initial evaluation included complete
physical examination, fiberoptic nasopharyngoscopy, chest
image (X-ray film and CT scan for N3 patients), MRI or
CT of the nasopharynx including skull base and neck re-
gion, blood routine tests, and complete metabolic chemis-
tries. Part of patients came from a clinical trial in which
the role of concurrent chemoradiotherapy were compared
regardless of the treatment technique, by this reason,
there were 129 patients received IMRT-SIB alone, and 142
patients received IMRT-SIB with current chemotherapy.
Radiotherapy
All patients were treated with 6MV-X by Varian 600C/D
linear accelerator, 5 fractions per week, with a total
treatment time of 6.5 weeks. The radiotherapy protocol
for IMRT-SIB alone and CCRT group was identical. The
whole neck IMRT technique was used to cover the pri-
mary lesion, nodal disease and entire neck including
supraclavicular region. The prescription dose to T1 and
T2 primary lesion (GTVp) was 70 Gy in 33 fractions at
2.12 Gy per fraction, while 74 Gy at 2.24 Gy per fraction
to T3 or T4 disease and involved retropharyngeal nodes
with largest diameter >1.5 cm, all positive lymph node
(GTVnd) were given 70 Gy at 2.12 Gy per fraction. The
elective radiation dose of 60 Gy at 1.82 Gy per fraction
encompasses the high risk regions including uninvolvedskull base, parapharyngeal space, posterior one-third of
nasal cavity and high risk nodal levels. If there were no
positive neck node in the neck, 50-54 Gy was delivered
to the bilateral lower neck and supraclavicular region
using a two-phase IMRT plan, with phase 1 IMRT plan
(28 treatment fractions) cover primary lesion, positive
nodes, high risk region and the lower neck/supraclavicu-
lar region, the phase 2 IMRT plan (5 treatment frac-
tions) cover only the primary lesion, positive nodes and
high risk regions. The dose constraints for major organs
at risk were shown as follow: brain stem with 3 mm
margin, Dmax < 54 Gy; spinal cord with 5 mm margin,
Dmax < 40 Gy; optic nerve, chiasm and temporal lobe,
Dmax < 54 Gy; parotid gland, V30-35 < 50%.
Chemotherapy
Planned chemotherapy was consisted of weekly intraven-
ous cisplatin at 30 mg/m2 for 7 weeks.
Management of residual primary lesions
At the end of treatment, there were 53 patients have re-
sidual disease at the primary sites that were documented
by MRI and/or endoscopic examination: 22 (15.5%) in
CCRT group and 31 (24.0%) in IMRT-SIB alone group.
Salvage local treatments include IMRT boost with a
mean dose of 8 Gy (range, 4-15 Gy) at 2-3 Gy per
fraction (n = 25) or Linac-based stereotactic radiotherapy
treatment (SRT) 20 Gy (range, 10-24 Gy) at 2-4 Gy per
fraction (n = 28).
Intra- and Post-treatment assessments
Tumor response was assessed at 50 Gy by clinical exam
including endoscopy and/or imaging study. If the vol-
ume and geometry of primary lesion and positive nodes
were changed significantly, the second CT-simulation
was performed and PTV volumes were modified corre-
sponding to significant GTVs regression. A new IMRT
plan was designed and started at the 29th treatment frac-
tion in order to avoid treatment break. Patients received
physical examination once a week during the treatment,
the radiotherapy related toxicities were graded according
to the Acute and Late Scoring Criteria of the Radiation
Therapy Oncology Group and chemotherapy-related toxic-
ities was evaluated by the CTC 2.0 or CTCAE3.0. If there
were grade 4 hematology toxicities and radiotherapy-
related mucositis occurred, the treatment would suspend
until the toxicities were recovered. The first post-treatment
follow-up was at 1 month, then every 3 months for the first
2 years, every 6 months thereafter for 3-5 years, and then
once a year.
Statistical methods
The statistic was performed by SPSS 13.0 software,
Kaplan-Meier method was used for calculating the survival,
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between the two groups.
Results
Patient characteristics
From November 2001 to December 2009, there were to-
tally 271 newly diagnosed locally advanced nasopharyn-
geal carcinoma treated with IMRT-SIB with or without
concurrent cisplatin-based chemotherapy in our institu-
tion. The characteristics of patients and treatment mo-
dality were shown in Table 1. There were well balanced
between the groups of IMRT-SIB alone and CCRT in
terms of gender, age, T classification, clinical stage, and
median RT dose to the GTVs.
Patient compliance
All patients completed RT as planned. Of 142 patients in
CCRT group, 127 (89.4%) received 5 and more cycles
of weekly chemotherapy, while 15 patients (10.6%) had
4 cycles or less.
Acute toxicities
Acute toxicities presenting in the groups of CCRT and
IMRT-SIB alone were: grade 3 mucositis, 24.1% versusTable 1 The characteristics of patients between IMRT-SIB
and CCRT
Items IMRT-SIB CCRT group p
n = 129 n = 142
No of patients (%) No of patients (%)
Gender 0.63
Male 92 (71.3) 105 (73.9)
Female 37 (28.7) 37 (26.1)
Age (year) 0.45
≤46 65 (50.4) 65 (45.8)
>46 64 (49.6) 77 (54.2)
Pathology 0.02
Non-keratinization
Differentiated 16 (9.3) 33 (23.2)
Undifferentiatied 113 (90.7) 109 (76.7)
T stage 0.45
T1 15 (11.6) 15 (10.6)
T2 27 (20.9) 29 (20.4)
T3 60 (46.5) 56 (39.4)
T4 27 (20.9) 42 (29.6)
Stage 0.18
III 89 (69.0) 87 (61.3)
IV 40 (31.0) 55 (38.7)
Median dose to GTV 74 74 0.12
IMRT-SIB: Intensity-modulated Radiotherapy with Simultaneous Integrated
Boost, CCRT: Concurrent chemoradiotherapy, GTV: Gross tumor volume.29.3% (P = 0.531); grade 2 and 3 neutropenia, 32.7% versus
8%, and 2% versus 0%, respectively (P = 0.008); grade 1
anemia 42.8% versus 24.5%, grade 2 anemia, 6% versus 0%
(p = 0.066). Grade 3 radiation dermatitis was 11.1% in
both CCRT and IMRT-SIB alone group. Only 1 patient in
CCRT group had grade 1 abnormal liver function tests.
There were no grade3 or higher anemia observed in either
group.
Treatment outcomes
The 5-year LC, OS, DFS and DMFS for the entire
group were 87.0%, 79.4%, 69.7 and 83.3%, respectively.
The 5-year LC, OS, DFS and DMFS of CCRT versus
IMRT-SIB-alone groups were 80.6% and 90.8% (P = 0.10),
71.7% and 83.2% (P = 0.201), 63.9% and 74.6% (P = 0.07),
79.6% and 86.0% (P = 0.27), respectively. For stage IVA
patients, the 5-year DFS, DMFS were 34.3% and 74.7%
(p = 0.01), 68.1% and 95.5% (p = 0.03) in CCRT (n = 39)
and IMRT-SIB alone group (n = 24), respectively. For
N0-1 patients, the 5-year DMFS were 67.3% and 96.9%
(p = 0.02) in CCRT (n = 32) and IMRT-SIB alone group
(n = 35).
Univariate analysis including age, gender, T stage and
clinical stage showed that there were no significant dif-
ferences of overall survival between CCRT and IMRT-
SIB alone groups (Table 2). No independent prognosis
factor was found by multivariate analysis. Figures 1 and
2 showed the local control of T3 and T4 patients.
Discussion
Several randomized clinical trials have demonstrated
that concurrent chemoradiotherapy is superior to radio-
therapy alone in the treatment of locoregionally ad-
vanced nasopharyngeal carcinoma. Al-sarraf et al. [1]
first reported that, compared to RT alone, concurrent
cisplatin chemoradiotherapy and adjuvant chemotherapy
with cisplatin and 5-Fluorouracil improved 5 years over-
all survival from 37% to 67% (p = 0.001). Wee et al. [6]
confirmed the advantage of CCRT with adjuvant chemo-
therapy in NPC epidemic regions. At the same period,
there were more and more data from nasopharyngeal
carcinoma epidemic areas showed that CCRT with or
without adjuvant chemotherapy improved the overall
survival when compared with RT alone [3,5,12]. These
clinical trials confirmed that advantage of CCRT with or
without adjuvant chemotherapy have improved local-
regional controls [1,5,6], some studies revealed decreases
of distant metastases [3,4,12] or both locoregional con-
trol and distant metastases [1,5,6]. The meta-analysis
also showed that the CCRT was superior to RT alone in
nasopharyngeal carcinoma epidemic areas [13]. In Chen’s
study [14], 508 patients were randomly assigned to the
CCRT followed by adjuvant chemotherapy (n = 251) and
CCRT alone group (n = 257), the 2-year overall survival
Table 2 The differences of treatment outcomes between CCRT and IMRT-SIB RT alone
Items LC P OS P DFS P DMFS P
CCRT RT CCRT RT CCRT RT CCRT RT
Gender 0.13 0.30 0.1 0.30
Male 77.9 89.9 70.2 77.8 62.9 72.3 79.9 81.4
Female 93.4 92.9 81.0 89.0 70.0 79.7 81.9 91.3
Age 0.09 0.23 0.08 0.24
≤46 87.2 94.8 73.7 90.2 68.5 79.7 77.6 90.2
>46 72.7 86.3 69.2 71.3 57.7 68.3 81.2 80.9
T3 89.2 92.4 0.93 69.3 84.0 0.45 63.2 68.4 0.31 77.4 81.9 0.82
T4 54.4 76.4 0.25 66.2 67.8 0.59 41.5 64.5 0.15 77.1 91.3 0.08
N0-1 73.4 84.0 0.85 72.2 76.7 0.35 51.5 82.9 0.09 67.3 96.9 0.02
N2-3 81.8 93.5 0.05 71.5 80.4 0.36 65.4 71.6 0.24 81.7 81.8 0.93
III 91.9 95.6 0.35 84.2 88.3 0.94 77.5 80.1 0.57 89.0 86.1 0.77
IV 63.8 63.6 0.352 54.3 71.5 0.24 43.6 61.3 0.15 64.8 86.3 0.12
IVA 47.1 78.6 0.11 62.2 69.2 0.43 34.3 74.7 0.01 68.1 95.5 0.03
IVB 84.0 64.0 0.55 50.0 73.9 0.41 55.6 45.0 0.62 62.5 73.1 0.86
Whole group 80.6 90.8 0.10 71.7 83.2 0.20 63.9 74.6 0.07 79.6 86.0 0.27
LC: Local control; OS: Overall survival; DFS: Disease-free survival; DMFS: Distant metastasis-free survival; RT: IMRT-SIB alone; CCRT: Concurrent chemoradiotherapy.
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dences, CCRT with or without adjuvant chemotherapy
has become the standard care for locoregionally advanced
nasopharyngeal carcinoma. However, most of these evi-
dences of standard treatment for locoregionally advanced
nasopharyngeal carcinoma were based on the 2D or non-
IMRT technique. As the IMRT technique has been widely
used in the last decades, and outcome of significant dis-
ease locoregional control, people started to reconsider the
role of CCRT. In Hong Kong NPC clinical trials (NPC
9901/9902), there were 50% patients received either 3D
conformal or IMRT, the results showed that there were no
significant differences in terms of overall survival between
the groups of CCRT and RT alone [15,16], although theFigure 1 The local control rate of T3 patients treated by
IMRT-SIB alone and CCRT.combined analysis of Hong Kong NPC 9901/9902 studies
revealed that patients who received CCRT did well in
overall survival [17].
Due to the complex anatomic location of nasopharynx,
it is technically challenging to deliver the definitive dose
to field without partially missing GTV coverage using
2-D RT technique. Such problem can be avoided with
the use of IMRT. Furthermore, with IMRT-SIB tech-
nique, there are two aspects of radiobiology rationale
to improve treatment results: shorten the overall treat-
ment time and increase the fractionation dose to gross
tumor volumes [18]. Several studies have confirmed
the safety and efficacy of IMRT-SIB in the treatment ofFigure 2 The local control rate of T4 patients treated by
IMRT-SIB alone and CCRT.
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[20] all reported very promising results of locally ad-
vanced nasopharyngeal carcinoma treated with IMRT-
SIB. In Xiao’s study [20], the prescription dose to NPC
GTVs was 68 Gy given in 30 fractions, 2.27 Gy per
fraction. The 5-year disease local control, disease-free
and overall survivals were 94.9%, 76.7% and 74.5%, re-
spectively. All toxicities were expected, and no exceed
treatment complications due to use of IMRT-SIB. In
the past 10 years, IMRT-SIB has been more often used
in locoregionally advanced head and neck cancer in-
cluding NPC treatments. Large sample studies from
NPC epidemic areas have demonstrated outcome im-
provements, see Table 3.
Our results did not demonstrate any significant differ-
ences in disease local control, overall survival, disease-
free survival and distant-metastasis free survival between
patients treated with IMRT-SIB alone or with concurrent
chemotherapy. Besides the better dose coverage pro-
vided by IMRT technique compared to the 2D tech-
nique, there were several other reasons may interpret
our results. One is the prescription doses to the gross
target volume were 74 Gy with 2.24 Gy/fraction for T3/
T4 lesions, the equivalent biological dose were 75.5 Gy
if given by 2 Gy/fraction according to the L-Q model,
which is about 7.8% increased of total dose when com-
pared to 70 Gy/2 Gy per fraction in the 2D era. If we
refer to dose-response curve for head and neck cancer
[27], with a γ37 of 2, the local control rate of our pa-
tients would be 15.6% higher than those patients who re-
ceived 70 Gy with 2 Gy/fraction in the 2D era, Actually,
the local control rate of RT alone groups in those ran-
domized clinical trials compared the concurrent chemo-
radiotherapy with radiotherapy alone in 2D era were
about 67%-72% [1,5,6], while the 5-year local control of
our study was 87%, which was about 15% higher, which
may extrapolate a potential increase of overall survival.
The reason for choosing a higher prescription dose for
T3/4 lesions was based on that there were larger tumor
burden in T3/4 lesions than those in T1/2 lesions, and aTable 3 The outcome of NPC treated by 2D technique and IM
Author and era No of pts Stage Treatment
technique
C
Lee 2005 [21] 2,687 I-IVB 2D 1
Yeh 2005 [22] 849 I-IVB 2D N
Yi 200 6 [23] 905 I-IVB 2D 2
Lin 2010 [24] 370 IIB-IVB IMRT S
Wang 2013 [25] 300 I-IVB IMRT S
Su 2011 [26] 865 I-IVB IMRT 2
This study 271 III-IVB IMRT 1
CCRT: Concurrent chemoradiotherapy; OS: Overall survival; PFS: Progression-free sur
*: Disease-free survival; Seq: Sequential, 2D: Two dimension; IMRT: Intensity-modulalarger tumor burden needs a higher dose to control. Sze
et al. [28] found that the overall correlation between T
stage and tumor volume was strongly significant in 308
nasopharyngeal carcinoma patients, the risk of local failure
was estimated to increase by 1% for every 1 cm3 increase
in primary tumor volume. Secondly, with IMRT-SIB, the
overall treatment time were 45 days for T3/4 patients,
there were 6 days reduced when compared with those
who treated by 2D conventional radiotherapy. Shorten
overall treatment time will benefit to overcome the tumor
cell repopulation and potentially improve disease local
control. Also, in our series, there were 53 patients with re-
sidual lesions at the end of treatment, received additional
boost either by IMRT or SRT. All these factors would
improve our treatment outcomes compared to those
come from 2D era in the literature. Our previously pub-
lished data also showed the patients with residual le-
sions received boost dose irradiation had the same local
control as those who had no residual disease at the
end of RT [24]. Teo et al. [29] reported dose-escalation
above 66 Gy significantly improved local control for
T1/T2a and T3/4 tumors when compared to 2D Ho's
technique.
Su et al. [26] also found that, comparing to IMRT
alone, adding chemotherapy to IMRT did not improve
the outcomes for locally advanced NPC. In their study,
of 603 patients with T3-4 N2-3 NPC treated with IMRT,
101 were treated with IMRT alone, 222 patients with
cisplatin-based CCRT (CCRT group), 207 patients with
induction chemotherapy followed by CCRT (IC + CCRT
group), 38 patients received IMRT with either induction
chemotherapy or adjuvant chemotherapy (IC or Adj
group) and 35 had CCRT followed by adjuvant chemo-
therapy (Con + Adj group). The 5 years overall survival
was 77.2% for IMRT group alone, 78.7% for CCRT
group, 73.4% for IC + CCRT group, 82.3% for IC or Adj
group and 80.6% for Con + Adj group (P = 0.59). There
were no significant survival differences no matter them
received chemotherapy or not. Of those with locoregion-
ally advanced NPCs who will benefit from CCRT or RTRT-SIB in epidemic areas
CRT OS % PFS % DMFS %
4% CCRT, 9% seq 75 63 81
o 59 52 74.7
.8% seq 76.1 58.4 79.8
eq without CCRT 89 (3 yr) 81(3 yr) * 86(3 yr)
tage III/IV with CCRT 86.1 (4 yr) NA 85.0
22 with CCRT 83.0 NA 84.0
42 with CCRT 79.4 63.9* 79.6
vival.
ted radiotherapy.
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AJCC staging system) patients from their previously ran-
domized trial [5] into high risk group and lower risk
group. The high risk group included patients who met at
least one of following criteria: nodal size >6 cm, supra-
clavicular node metastases, 1992 AJCC stage T4N2, mul-
tiple neck node metastases with at least 1 node >4 cm;
the others without any high risk factors were in low risk
group. The results showed that only low risk group pa-
tients benefited from CCRT compared to the RT alone.
The 5-year disease LC and OS were 95.1% and 85.3% in
CCRT group, the disease local control improvement has
been translated into an OS benefit. But, when compared
to the Lin’s data, in our study, LC and OS for stage III
patients (similar to Lin’s lower risk group) treated with
IMRT-SIB alone were 95.6% and 88.3%, is similar to
those in Lin’s lower risk group who treated with CCRT.
That is to say, in some selected patients (for example,
UICC stage III patients), IMRT-SIB alone may be an al-
ternative treatment choice.
Several pitfalls need to be addressed. Selection bias in a
retrospective study could have impacted on our results.
However, we included all consecutive patients with stage
III and non-metastatic stage IV NPC treated with IMRT-
SIB in our institution except for those received neo- or ad-
juvant chemotherapy or molecular target drugs. Second,
the cumulative cisplatin dose from our weekly chemother-
apy regimen was 180-210 mg/m2, which was lower than
the recommended standard total dose of 300 mg/m2, as
there was a positive relationship between the total cisplatin
dose and treatment outcomes locally advanced squamous
cell carcinoma of head and neck [31]. As CCRT with high
acute treatment-related toxicities in patients who received
cisplatin regimen of 100 mg/m2, about 30% patients could
not receive the third cycle of cisplatin [32]. Kim et al. [33]
compared and analyzed the tumor response, the overall
survival, the toxicity and the chemotherapy dose intensity
in the patients with locally advanced nasopharyngeal can-
cer who were treated with a 3-week cycle of 100 mg/m2
cisplatin or 30 mg/m2 weekly cisplatin, the author con-
clude that weekly 30 mg/m2 cisplatin-based CCRT is a
practical, feasible cisplatin schedule for the patients with
locally advanced nasopharyngeal cancer in regard to de-
creasing the interruption of radiation treatment and the
treatment-related acute toxicities. So the total dose in our
study might be reasonable. We are not clear about the
worse outcomes in terms of DFS and DMFS in CCRT
group compared to IMRT-SIB alone group for stage IVA
and N0-1 patients, the possible reasons maybe the sample
size and the bias of a retrospective study.
Conclusion
IMRT-SIB alone achieved similar treatment outcomes as
compared to concurrent chemotherapy and IMRT-SIBin terms of disease local control and overall survival.
However, such results need further investigation in a
prospective randomized clinical trial.
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